NEW YORK (GenomeWeb) – Stand Up To Cancer-sponsored research has shown that genotyping liquid biopsy and tumor biopsy does not yield identical results and concluded that no single diagnostic test can be considered a "gold standard."
A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.
Try GenomeWeb Premium now.
Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
While gene therapies may have high price tags, they could be cheaper than the cost of managing disease, according to MIT's Technology Review.
Researchers are looking for markers that indicate which cancer patients may respond to immunotherapies, the Associated Press writes.
Nature News writes that researchers are still wrangling over the role of the p-value.
In Nature this week: paternal age associated with de novo mutations in children, and more.